Novolog (Pharm-Up 1966) Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Aviad Bossi

İcra Kurulu Başkanı

₪1.8m

Toplam tazminat

CEO maaş yüzdesi	42.3%
CEO görev süresi	1.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	7.2yrs

Son yönetim güncellemeleri

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29

Recent updates

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Nov 05

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

Jul 25

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

May 07

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Apr 14

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Mar 24

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 09

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

Feb 15

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Jan 25

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Dec 08

CEO Tazminat Analizi

Aviad Bossi'un ücretlendirmesi Novolog (Pharm-Up 1966)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₪6m
Jun 30 2024	n/a	n/a	-₪18m
Mar 31 2024	n/a	n/a	-₪20m
Dec 31 2023	₪2m	₪762k	-₪42m

Tazminat ve Piyasa: Aviad 'ın toplam tazminatı ($USD 493.74K ) IL pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 648.14K ).

Tazminat ve Kazançlar: Aviad şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Aviad Bossi (48 yo)

1.3yrs

Görev süresi

₪1,802,000

Tazminat

Mr. Aviad Bossi is Chief Executive Officer of Novolog (Pharm-Up 1966) Ltd from July 01, 2023.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aviad Bossi	Chief Executive Officer	1.3yrs	₪1.80m	Veri yok
Nega Hon	Vice President of Information Systems	1.9yrs	₪1.08m	Veri yok
Assi Weshler	Chief Executive Officer of Trilog & Medicare to Home	no data	₪2.33m	Veri yok
Yehiel Asia	Chief Executive Officer of Ein Tal	no data	₪1.25m	Veri yok
Rafi Friedman	Chief Executive Officer of Mediplast Israel Ltd.	6.8yrs	₪1.19m	Veri yok
Yaniv Vidavsky	Chief Financial Officer	less than a year	Veri yok	Veri yok
Adi Marx	Vice President of Business Development & Special Projects	1.8yrs	Veri yok	Veri yok
Gali Srogati	Vice President of Human Resources	less than a year	Veri yok	Veri yok
David Shmuelov	Chief Executive Officer of Drug Distribution & Medical Device Company	5.5yrs	Veri yok	Veri yok
Amitai Gridish	Chief Executive Officer of Target Care Services Ltd.	5.5yrs	Veri yok	Veri yok
Ofer Amar	Chief Executive Officer of Mediquip Ltd.	7.1yrs	₪2.03m	Veri yok
Avir Dor	Chief Executive Officer of Generation Pharmaceuticals Ltd.	13.5yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: NVLG 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tamar Gottlieb	Independent Non-Executive Director	2yrs	Veri yok	Veri yok
David Ben-Ami	Independent External Director	7.5yrs	Veri yok	Veri yok
Miriam Shave	Independent External Director	7.5yrs	Veri yok	Veri yok
Itay Taleh	Director	8.3yrs	Veri yok	Veri yok
Demi Dor	Chairman of the Board	6.9yrs	₪293.00k	Veri yok
Varda Shalev	Director	1.9yrs	Veri yok	Veri yok

7.2yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NVLG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.2 yıldır).

Novolog (Pharm-Up 1966) Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Novolog (Pharm-Up 1966) Ltd, Annual General Meeting, Aug 05, 2024

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Insufficient new directors

Insufficient new directors

Insufficient new directors

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Recent updates

Upcoming dividend of ₪0.02 per share

Third quarter 2024 earnings released: EPS: ₪0.023 (vs ₪0.001 in 3Q 2023)

Now 20% overvalued after recent price rise

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2024 Results on Nov 20, 2024

Upcoming dividend of ₪0.029 per share

Second quarter 2024 earnings released: EPS: ₪0.026 (vs ₪0.023 in 2Q 2023)

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2024 Results on Sep 04, 2024

Novolog (Pharm-Up 1966) Ltd, Annual General Meeting, Aug 05, 2024

First quarter 2024 earnings released: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023)

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2024 Results on May 21, 2024

Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022)

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: ₪0.001 (vs ₪0.02 in 3Q 2022)

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: ₪0.023 (vs ₪0.024 in 2Q 2022)

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

First quarter 2023 earnings released: ₪0.02 loss per share (vs ₪0.024 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: ₪0.094 (vs ₪0.084 in FY 2021)

Investor sentiment deteriorates as stock falls 17%

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2022 Results on Mar 20, 2023

Investor sentiment deteriorates as stock falls 15%

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Third quarter 2022 earnings released: EPS: ₪0.02 (vs ₪0.02 in 3Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: EPS: ₪0.024 (vs ₪0.02 in 2Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2022 Results on Aug 10, 2022

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2022 Results on May 18, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2021 Results on Mar 14, 2022

Third quarter 2021 earnings released: EPS ₪0.022 (vs ₪0.021 in 3Q 2020)

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Upcoming dividend of ₪0.032 per share

Full year 2020 earnings released: EPS ₪0.086 (vs ₪0.026 in FY 2019)

Novolog (Pharm-Up 1966) Ltd to Report Fiscal Year 2020 Results on Mar 17, 2021

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

New 90-day low: ₪2.76

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Novolog (Pharm-Up 1966) Ltd announced that it has received ILS 119.999999 million in funding

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Third quarter 2020 earnings released: EPS ₪0.021

Market bids up stock over the past week

New 90-day high: ₪3.20

New 90-day high - ₪3.09

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş